原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征诊治进展*

doi:10.3969/j.issn.1672-5069.2023.02.038

Abstract

Abstract: Objective Primary biliary cholangitis(PBC)is characterized by a chronic autoimmune intrahepatic cholestasis,and autoimmune hepatitis (AIH) is a liver parenchymal inflammation mediated by autoimmune reaction. When the two entities coexist in a given patient, we call it "PBC-AIH overlap syndrome (PBC-AIH OS)". The prevalence of PBC-AIH OS is low, but it progresses faster and has a poorer prognosis. The clinical diagnosis and the choice of treatment are still challenging. Therefore, in this article, we reviewed the latest progress in the definition, epidemiology, clinical features, diagnosis, treatment and prognosis of patients with PBC-AIH OS, in order to help the appropriate diagnosis and treatment of the disease.

Key words: Primary biliary cholangitis, Autoimmune hepatitis, Overlap syndrome, Diagnosis, Treatment

Ma Li, Gao Lili, Duan Xuefei. Diagnosis and treatment of patients with primary biliary cholangitis-autoimmune hepatitis overlap syndrome[J]. Journal of Practical Hepatology, 2023, 26(2): 301-304.

References

[1] Rust C, Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol, 2008, 14(21): 3368-3373.
[2] Czaja AJ. Cholestatic phenotypes of autoimmune hepatitis. Clin Gastroenterol Hepatol, 2014, 12(9): 1430-1438.
[3] Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol, 2011, 54(2): 374-385.
[4] European Association for the Study of the Liver. EASLclinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol, 2017, 67(1): 145-172.
[5] Lyu T, Chen S, Li M, et al. Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis. J Gastroenterol Hepatol, 2021, 36(6): 1423-1434.
[6] Cheung KS, Seto WK, Fung J, et al. Epidemiology andnatural history of primary biliary cholangitis in the Chinese: a territory-based study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterol, 2017, 8(8): e116.
[7] Tanaka A, Mori M, Matsumoto K, et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res, 2019, 49(8): 881-889.
[8] Floreani A, Franceschet I, Cazzagon N. Primary biliary cirrhosis: overlaps with other autoimmune disorders. Semin Liver Dis, 2014, 34(3): 352-360.
[9] Hu Z, Ni P, Fan X, et al. Past hepatitis B virus infection was not associated with poorer response or the UK-PBC risk score in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol, 2019, 31(2): 277.
[10] 杨宁, 孙可帅, 田思远, 等. 伴自身免疫性肝炎特征的原发性胆汁性胆管炎的临床特征. 解放军医学杂志, 2021, 46(1): 36-41.
[11] Jiang Y, Xu BH, Rodgers B, et al. Characteristics and inpatient outcomes of primary biliary cholangitis and autoimmune hepatitis overlap syndrome. J Clin Transl Hepatol, 2021, 9(3): 392-398.
[12] 中国医师协会风湿免疫科医师分会自身抗体检测专业委员会, 国家风湿病数据中心, 国家皮肤与免疫疾病临床医学研究中心. 自身免疫性肝病相关自身抗体检测的临床应用专家共识. 中华内科杂志, 2021, 60(7): 619-625.
[13] Bauer A, Habior A. Detection of autoantibodies against nucleoporin p62 in Sera of patients with primary biliary cholangitis. Ann Lab Med, 2019, 39(3): 291-298.
[14] 党富涛, 唐映. 自身抗体在原发性胆汁性胆管炎中的诊断及预后价值. 临床肝胆病杂, 2020, 36(5): 1164-1166.
[15] Sebode M, Weiler-Normann C, Liwinski T, et al. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol, 2018, 9: 609.
[16] Himoto T, Yoneyama H, Kurokohchi K, et al. Clinical significance of autoantibodies to p53 protein in patients with autoimmune liver diseases. Can J Gastroenterol, 2012, 26(3): 125-129.
[17] Nguyen HH, Shaheen AA, Baeza N, et al. Evaluation of classical and novel autoantibodies for the diagnosis of primary biliary cholangitis-autoimmune hepatitis overlap syndrome (PBC-AIH OS). PLoS One, 2018, 13(3): e0193960.
[18] Malik N, Venkatesh SK. Imaging of autoimmune hepatitis and overlap syndromes. Abdom Radiol (NY), 2017, 42(1): 19-27.
[19] Wu HM, Sheng L, Wang Q, et al. Performance of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis-primary biliary cholangitis overlap syndrome. World J Gastroenterol, 2018, 24 (6): 737-743.
[20] Lee BT, Wang Y, Yang A, et al. IgG: IgM ratios of liver plasma cells reveal similar phenotypes of primary biliary cholangitis with and without features of autoimmune hepatitis. Clin Gastroenterol Hepatol, 2021, 19(2): 397-399.
[21] Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol, 2010, 8(6): 530-534.
[22] Liu F, Pan ZG, Ye J, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: simplified criteria may be effective in the diagnosis in Chinese patients. J Dig Dis, 2014, 15(12): 660-668.
[23] 张骏飞, 许何明, 宋海燕, 等. 自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征: 巴黎标准诊断中国患者灵敏度低. 实用肝脏病杂志, 2019, 22(4): 537-540.
[24] Bonder A, Retana A, Winston DM, et al. Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol, 2011, 9(7): 609-612.
[25] Wang QX, Selmi C, Zhou XM, et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun, 2013, 41: 140-145.
[26] Wang G, Tanaka A, Zhao H, et al. The Asian Pacific Association for the Study of the liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int, 2021, 15(2): 223-257.
[27] Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology, 2020, 72(2): 671-722.
[28] Zhang W, De D, Mohammed KA, et al. New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome. Hepatol Commun, 2018, 2(3): 245-253.
[29] Montano-Loza AJ, Corpechot C. Definition and management of patients with primary biliary cholangitis and an incomplete response to therapy. Clin Gastroenterol Hepatol, 2021, 19(11): 2241-2251 e2241.
[30] Chazouilleres O, Wendum D, Serfaty L, et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol, 2006, 44(2): 400-406.
[31] 杨宁, 田思远, 张苗, 等. 熊去氧胆酸联合糖皮质激素治疗伴自身免疫性肝炎特征原发性胆汁性胆管炎的效果分析. 解放军医药杂志, 2021, 33(3): 72-77.
[32] Martinez Casas OY, Diaz Ramirez GS, Marin Zuluaga JI, et al. Autoimmune hepatitis - primary biliary cholangitis overlap syndrome. Long-term outcomes of a retrospective cohort in a university hospital. Gastroenterol Hepatol, 2018, 41(9): 544-552.
[33] Yang F, Wang Q, Wang Z, et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis. Clin Rev Allergy Immunol, 2016, 50(1): 114-123.
[34] Yoshioka Y, Taniai M, Hashimoto E, et al. Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: Importance of corticosteroid therapy. Hepatol Res, 2014, 44(9): 947-955.

Diagnosis and treatment of patients with primary biliary cholangitis-autoimmune hepatitis overlap syndrome

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bai Tingting, Liu Yuyi, Chen Dongfeng. Diagnosis and differential diagnosis of patients with hepatic vascular diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 153-155.
[2]	Deng Yuting, Zhou Junying. Budd-Chiari syndrome:Current state of the art [J]. Journal of Practical Hepatology, 2023, 26(2): 156-159.
[3]	Liu Gang, Zhang Hao, Hu Jun. Changes of serum miR-183-5p and miR-96-5p levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 197-201.
[4]	Ling Jiahui, Ni Meixin, Han Lili, et al.. Serum cytokine changes in patients with autoimmune hepatitis receiving magnesium isoglycyrrhizinate treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 214-217.
[5]	Wang Yan, Zhou Jing, Han Jun. Clinicopathological features of patients with autoimmune hepatitis and drug-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(2): 218-221.
[6]	Dou Jing, Xu Qiang, Wang Zhuanguo, et al.. Clinical and liver histopathological features of patients with autoimmune hepatitis with low serum IgG and normal alanine aminotransferase levels [J]. Journal of Practical Hepatology, 2023, 26(2): 222-225.
[7]	Li Yanfen, Zhang Xiaowen, Wang Yanru, et al.. Rescuing therapy of obeticholic acid and fibrates in patients with primary biliary cholangitis without complete response to ursodeoxycholic acid treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 226-229.
[8]	Zhang Lili, Zhang Chun, Wang Yitong, et al.. Clinical characteristics of systemic sclerosis complicated with primary biliary cholangitis and portal hypertension: Analysis of 12 cases [J]. Journal of Practical Hepatology, 2023, 26(2): 230-233.
[9]	Deng Kexin, Luo Hongchun. Evaluation of bacterial infection by common hematological indexes in patients with acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2023, 26(2): 242-245.
[10]	Shu Kaifeng, Mi Chun, Liu Weiwei, et al.. Diagnostic performance of high-frequency and color Doppler ultrasonography in judging the benign and malignant gallbladder polyps [J]. Journal of Practical Hepatology, 2023, 26(2): 286-289.
[11]	Huang Xiaoquan, Chen Shiyao. Standardization treatment of patients with portal hypertension and gastroesophageal variceal bleeding [J]. Journal of Practical Hepatology, 2023, 26(1): 1-3.
[12]	Wang Haoyu, Zhou Juanyan, Liu Ru, et al. Changes of peripheral blood NKp46⁺ILC3 cells and Th17 cells in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2023, 26(1): 39-42.
[13]	Liu Nannan, Li Wei, Zhao Shousong. Diagnostic performance of simplified animal nomenclature test in predicting minimal hepatic encephalopathy in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(1): 83-86.
[14]	Jiang Huizhen, Chen Jun, Chen Chunmei, et al. Performance of quantitative parameters by dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of benign and malignant hepatic space-occupying lesions [J]. Journal of Practical Hepatology, 2023, 26(1): 100-103.
[15]	Gao Xiangrui, Liu Hongyan, Zhang Huai, et al. Differential diagnosis of hepatic hemangioma and hepatocellular carcinoma by multi-b-value diffusion-weighted imaging of high-field magnetic resonance [J]. Journal of Practical Hepatology, 2023, 26(1): 104-107.